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Dr Casare Maffei has provided us with a fascinat-
ing case report (patient M). Dr Maffei describes 
this complex and challenging patient and presents 
an excellent synopsis of her developmental, 
clinical, family and social history. Her varied 
and evolving symptomatology includes disordered 
binge eating, great interpersonal diffi culties, severe 
self-mutilating behaviours including suicide 
attempts, and extreme substance abuse of prescrip-
tion medications. Also present are depersonaliza-
tion experiences and somatic delusional beliefs (M 
considers food ‘dirty’ and believes that in some way 
food will damage her bowels). Adding to the treat-
ment challenge is that the patient often gives 
vague and/or simplistic descriptions to her thera-
pists and doctors, apparently being unable to utilize 
higher-order abstract reasoning and communica-
tion skills in therapeutic venues.
We are introduced to M as a 31-year-old unmar-
ried female, living in her parents’ home. She has 
successfully completed a law degree, but has never 
worked in this fi eld. She took 9 years to complete 
her degree. Great interpersonal diffi culties inter-
fere with her current job as a secretary. She sought 
treatment at age 24 because of severe self-
mutilating behaviours, mainly forearm cutting and 
burning, and impulsive behaviours in multiple 
areas, namely binge eating and medication abuse.
M has experienced a wide variety of psychiatric 
symptoms throughout her life. These include, in 
order of presentation, the following: obsessions and 
compulsions; beginning at age 11, self-injurious be-
haviours; and beginning at age 16, disordered 
eating behaviour, with binging, laxative abuse and 
induced vomiting. She has had numerous suicidal 
or parasuicidal attempts/gestures by drug overdose. 
Two of these attempts required hospitalization. 
The patient has also experienced dissociative type 
experiences, and she describes magical thinking 
about being able to be in contact with the dead.
Patient M’s Axis II diagnosis is borderline per-
sonality disorder (BPD) with schizotypal traits. 
She meets DSM-IV criteria, via the Structured 
Clinical Interview D (SCID-II). She fulfi ls seven 
of the nine BPD criteria, in addition to four 
schizotypal personality disorder criteria. The use of 
antipsychotic medications in schizotypal person-
ality disorder has been studied for the past 25 
years, and for at least the past 20 years, the use of 
these medications in BPD has also been studied. 
Soloff’s 1998 review suggested that low doses of 
fi rst- generation antipsychotic drugs were effective 
in reducing cognitive perceptual abnormalities in 
both borderline and schizotypal personality disor-
ders. M’s psychotic and parapsychotic symptoms, 
specifi cally somatic delusions, odd beliefs, magical 
thinking and unusual perceptual experiences 
argue for trials of antipsychotic medication. Early 
in her treatment course, she received fi rst-generation 
antipsychotic agents, including haloperidol and 
Commentary
Copyright © 2010 John Wiley & Sons, Ltd 4: 224–228 (2010)
DOI: 10.1002/pmh
225
chlorpromazine. She was noted to ‘misuse’ chlo-
rpromazine by taking much higher doses than pre-
scribed and resorted to stealing and forging 
prescriptions. M’s chaotic and worrisome symp-
toms continued, and within a year of initiation of 
haloperidol and chlorpromazine, as well as pre-
scription drugs from other classes, she stopped all 
psychiatric treatment.
A very condensed account of her treatment 
from ages 24–31 includes short hospital stays, brief 
trials of outpatient psychotherapy, pharmacother-
apy and day hospitalization. M’s usual pattern was 
to terminate all treatments early and to avoid 
restarting treatment. She also self-imposed a 4-year 
treatment hiatus from ages 25–29. While pharma-
cotherapy was started coincident with her fi rst 
psychiatric contact at age 24, she did not receive 
atypical antipsychotic medications until very late 
in the described treatment course. Exploration of 
her treatment experience with several atypical 
antipsychotic medications will follow, in addition 
to the research fi ndings that have provided a rea-
sonable rationale for choosing drugs in this class 
to treat BPD.
Clozaril was the fi rst atypical (novel) antipsy-
chotic administered to our patient, for several cited 
reasons. One was the thought that the necessity 
of frequent blood draws to monitor white blood 
cell counts would make attendance at regular 
medical visits imperative. Also, it was hoped that 
previous misuse of prescribed medication, which 
had been so problematic for this patient, would be 
minimized by her agreement to this plan. M 
responded well to this fi rst chosen atypical antip-
sychotic medication; she stopped self-cutting 
behaviours and reduced laxative abuse. Evidence 
for use of clozapine in BPD patients with psychotic 
features and self-mutilation is clear (Chengappa, 
Ebeling, Kang, Levine, & Parepally, 1999). A 
preliminary study by Frankenburg and Zanarini 
(1993) examined the effects of clozapine on 15 
patients with ‘prolonged and/or pronounced psy-
chotic symptoms of an atypical nature’. On the 
Brief Psychiatric Rating Scale (BPRS), subjects’ 
ratings decreased signifi cantly after 2–9 months of 
treatment for positive, negative and overall symp-
tomatology. Another early open study of low-dose 
clozapine was published by Benedetti, Sforzini, 
Colombo, Maffei, and Smeraldi (1998). Twelve 
borderline personality disordered inpatients with 
psychotic-like symptoms were studied. The clozap-
ine dose was up titrated in each individual patient 
using complete disappearance of psychotic 
symptoms as the dosage endpoint. BPRSs were 
performed by non-blinded clinicians and showed 
statistically signifi cant decreases in BPRS scores 
within the fi rst 3 weeks of treatment, indicating 
decreases in psychotic-like symptoms. Impulsive 
behaviours and depression-related symptoms also 
diminished. In this publication, Benedetti et al. 
discuss the rapid decrease in psychotic symptoms 
in addition to broad improvement across all 
symptom clusters, achieving these results with very 
low doses of clozapine (25–100 mg). A recently 
published meta-analyses of multiple drug classes for 
treatment of severe personality disorders reveals 
that no randomized controlled trial (RCT) study-
ing clozapine for treatment of personality disorder 
has been done to date (Ingenhoven, Lafay, Rinne, 
Passchier, & Duivenvoorden, 2010). Perhaps the 
most obvious reason for the lack of RCTs for cloza-
pine in the treatment of BPD is the aforemen-
tioned potentially life-threatening side effect of 
agranulocytosis (Lambertenghi Deliliers, 2000). In 
clinical practice, clozapine is reserved as a third- or 
fourth-line agent to treat psychosis as it is much 
more cumbersome to use in comparison with other 
drugs in its class. It would be logical to assume that 
researchers have taken these diffi culties of clinical 
use into consideration and have decided not to 
pursue systematic RCTs of clozapine.
The second atypical antipsychotic given to our 
patient was risperidone. There have not been 
RCTs of risperidone in patients with BPD, but 
there is one RCT of this agent, published by 
Koenigsberg et al. (2003), for the treatment of 
schizotypal personality disorder. This 9-week study 
included 23 outpatients with only a very low per-
centage (20%) having co-morbid BPD. The start-
ing dose of risperidone in this study was 0.25 mg, 
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with the highest dose being 2.0 mg. This study 
utilized the Positive and Negative Syndrome Scale 
(PANSS), and showed that subjects receiving 
active medication had signifi cantly lower scores on 
the PANSS negative, positive and general sub-
scales by the end of the study. As patient M had 
signifi cant schizotypal features, this drug was a 
very logical second choice based on the available 
literature. However, the patient’s symptoms 
appeared to worsen on low-dose risperidone 
(0.5 mg/day), with two incidents of self-cutting; 
therefore, after 3 weeks of risperidone treatment, 
she was switched to olanzapine. Risperidone has 
the highest incidence among the atypicals of 
extrapyramidal symptoms (EPS) (Weiden, 2007). 
Rapidly escalating dosage also puts patients at 
greater risk for this side effect. Also, specifi c patient 
qualities, such as male gender and young age, put 
patients at higher risk for EPS. On the other hand, 
when taking metabolic effects into account, risp-
eridone has a relatively low risk of causing diabetes 
and obesity (Murashita et al., 2007).
Olanzapine is the best systematically studied 
atypical antipsychotic medication via RCTs 
(Abraham & Calabrese, 2008). It was the third 
atypical antipsychotic medication chosen by M’s 
psychiatrist after withdrawal of clozaril was neces-
sitated by the appearance of the serious side effect 
of agranulocytosis, and a brief trial of low-dose 
risperidone was regarded as a treatment failure. 
RCTs using olanzapine to treat personality-disor-
dered patients began to appear in the literature in 
2001 (Zanarini & Frankenburg, 2001). While this 
fi rst study’s sample contained only 28 patients 
diagnosed with BPD, the outcome measures were 
very enlightening. The authors found that on 
self-ratings of paranoia, anxiety, anger/hostility 
and interpersonal sensitivity using scales on the 
Symptom Checklist-90 (SCL-90), there was a 
statistically signifi cant improvement over time (6 
months) for the olanzapine-treated group. However, 
there was no difference in self-ratings on the 
depression scale of the SCL-90 between the olan-
zapine and control groups. Bogenschutz and Nurn-
berg (2004) published a 12-week placebo-controlled 
trial with olanzapine, using adjusted dosing with a 
range of 2.5–20 mg/day. The authors used outcome 
measures of the Clinical Global Impression Scale 
(CGI) applied to each of the DSM-IV criteria for 
BPD (CGI-BPD) as well as an overall CGI rating. 
By week 4, there was signifi cant separation on 
these measures between the olanzapine and control 
groups. A third and very interesting study utilizing 
olanzapine was done by Soler et al. (2005). Their 
methodology involved initial treatment of 60 
patients with dialectical behaviour therapy (DBT), 
and while continuing this structured psychothera-
peutic treatment, the subjects were randomized 
into DBT alone and DBT plus olanzapine groups. 
Findings of this 12-week outpatient trial included 
greater improvement in the olanzapine plus DBT 
cohort on both the Hamilton Depression Rating 
Scale (HAM-D), and the Hamilton Anxiety 
Rating Scale (HAM-A). There was also a greater 
reduction in reports of aggressive/impulsive behav-
iour in the olanzapine-treated group. In each of the 
above studies, statistically signifi cant greater weight 
gain in olanzapine groups was also a reported 
outcome. In our study of patient M, we learn that 
the initiation of olanzapine had ‘satisfying results’. 
Specifi cally, Dr Maffei explains that this patient 
has shown slow but progressive improvement, with 
better control of impulsivity and her behaviours of 
substance and laxative abuse ended during the 
most recent 2 months of treatment described by 
this case report. Soler et al. (2005) reported signifi -
cant weight gain with olanzapine, without a dose-
dependent relationship. M’s metabolic status 
should be monitored closely as long as she remains 
on any atypical antipsychotic drug. Patients with 
disordered eating show decreased adherence to a 
medication when weight gain is a possible side 
effect.
The atypical antipsychotic aripiprazole was not 
utilized in M’s treatment. However, for complete-
ness, a description of the RCT done by Nickel, 
Loew, and Gil (2007) is included here. The authors 
recognized that given the novel mechanism of 
action of aripiprazole and the evidence for its effi -
cacy in the treatments of schizophrenia, schizoaf-
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fective disorder, manic and mixed states of bipolar 
disorder, it was reasonable to study this medica-
tion’s usefulness in treating BPD. A double-blind, 
placebo-controlled study involving 52 subjects 
with confi rmed BPD diagnosis by SCID-II was 
completed over an 8-week period. Improvement 
was measured by the SCL-90-R, HAM-D, HAM-A 
and the State-Trait Anger Expression Inventory. 
Signifi cant separation between the active treat-
ment and placebo groups was found using each of 
the above measurements. The authors found that 
all SCL-90-R scores were improved in the aripipra-
zole group, but were particularly improved on the 
obsessive-compulsive, insecurity in social contacts, 
depression, anxiety, aggressiveness/hostility, phobic 
anxiety, paranoid thinking and psychoticism 
scales.
Our patient’s presentation can be characterized 
as variable, complex and severe. Most of her symp-
toms including her compulsive neatness, social 
avoidance, suicide attempts, paranormal beliefs/
magical thinking, paranoia about food and con-
tamination, and her early aggressive behaviour 
with her brother as well as self-aggression would 
each fi t into one or several of the above domains. 
Therefore, it is reasonable to think of aripiprazole 
as a possible future treatment for this patient. 
When using aripiprazole to treat BPD, common 
side effects include insomnia, anxiety and head-
ache (Mobascher, Mobascher, Schlemper, Win-
terer, & Malevani, 2006). In BPD, no RCTs for 
the following atypical antipsychotics have been 
reported to date: quetiapine, ziprasidone, iloperi-
done and asenapine.
Discussion/future directions
The case of patient M provides us with a rich 
tapestry of clinical history, symptoms and treat-
ments. The fi eld has begun to embrace the neces-
sity for standardization of methods needed to study 
atypical antipsychotics, mood stabilizers and other 
agents in the treatment of BPD (Saunders & Silk, 
2009). If followed, the recommendations of Saun-
ders and Silk calling for sorting target symptoms 
into trait dimensions and utilization of identical 
research templates would be invaluable in unravel-
ling the crazy quilt of current research. Use of 
much larger sample sizes such as those available in 
the Collaborative Longitudinal Personality Disor-
ders Study (Sanislow et al., 2002) will also be 
imperative in realizing the goal of specifi c research-
based treatment recommendations for BPD.
Many of us have diffi cult patients similar to M 
in our own practices. Currently, we face many 
challenges in achieving early improvement and 
lasting relief for these patients. New evidence-
based algorithms will hopefully be developed to 
provide systematic treatment recommendations for 
use of atypical antipsychotic medications, sorely 
needed and long overdue, in BPD.
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